7 results match your criteria: "Geriatric Psychiatry Service University Hospitals of Geneva (HUG) Thônex Switzerland.[Affiliation]"
Functional network centrality indicates interactions between APOE4 and age across the clinical spectrum of Alzheimer's Disease.
Neuroimage Clin
September 2024
Faculty of Medicine, University of Geneva (UNIGE), Geneva, Switzerland; Geriatric Psychiatry Service, University Hospitals of Geneva (HUG), Thônex, Switzerland.
Advanced age is the most important risk factor for Alzheimer's disease (AD), and carrier-status of the Apolipoprotein E4 (APOE4) allele is the strongest known genetic risk factor. Many studies have consistently shown a link between APOE4 and synaptic dysfunction, possibly reflecting pathologically accelerated biological aging in persons at risk for AD. To test the hypothesis that distinct functional connectivity patterns characterize APOE4 carriers across the clinical spectrum of AD, we investigated 128 resting state functional Magnetic Resonance Imaging (fMRI) datasets from the Alzheimer's Disease Neuroimaging Initiative database (ADNI), representing all disease stages from cognitive normal to clinical dementia.
View Article and Find Full Text PDFUnlabelled: Gamma-hydroxy-butyric acid (GABA) and glutamate are neurotransmitters with essential importance for cognitive processing. Here, we investigate relationships between GABA, glutamate, and brain ß-amyloid (Aß) burden before clinical manifestation of Alzheimer's disease (AD). Thirty cognitively healthy adults (age 69.
View Article and Find Full Text PDFIntroduction: Establishing valid diagnostic strategies is a precondition for successful therapeutic intervention in Alzheimer's disease (AD).
Methods: One hundred forty-four healthy 75-year-old participants from the Vienna-Transdanube-Aging longitudinal cohort study were tested for neuroaxonal damage by single molecular array (Simoa) plasma neurofilament light chain (NfL) levels at baseline, 30, 60, and 90 months, and onset of AD dementia. Individual risk for sporadic AD was estimated by continuous shrinkage polygenic risk score (PRS-CS, genome-wide association study).
Microglia and Other Cellular Mediators of Immunological Dysfunction in Schizophrenia: A Narrative Synthesis of Clinical Findings.
Cells
August 2023
Department of Psychiatry, Adult Psychiatry Service, University Hospitals of Geneva (HUG), 1207 Geneva, Switzerland.
Article Synopsis
- Schizophrenia is a complicated mental health disorder that might be linked to problems with the immune system.
- The review highlights new evidence connecting immune dysfunction to schizophrenia's clinical features, expanding on previous genetic and molecular research.
- It proposes a hypothesis about how immune cells, especially microglia, play a role in the development of schizophrenia, aiming to improve understanding and treatment of the disorder.
How non-drug interventions affect the quality of life of patients suffering from progressive cognitive decline and their main caregiver.
Aging (Albany NY)
June 2020
Leenaards Memory Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Article Synopsis
- The study explores the impact of non-drug interventions (NDIs) on the quality of life (QOL) for patients with age-related neurodegenerative diseases and their caregivers, revealing no significant difference in QOL between single and multiple NDIs.
- Socio-demographic factors, such as age, gender, and caregivers' occupational status, significantly influenced the QOL of both patients and caregivers throughout the study.
- The findings suggest that maintaining consistent NDIs over time is crucial for preserving the QOL of patients and reducing caregivers' anxiety and depression.
Trajectory of disability and quality-of-life in non-geriatric and geriatric survivors after severe traumatic brain injury.
Brain Inj
January 2018
c Division of Anaesthesiology , University Hospitals of Geneva (HUG), Geneva , Switzerland.
Objective: The objective was to investigate disability and health-related quality-of-life (HRQoL) 3, 6 and 12 months after traumatic brain injury (TBI) in non-geriatric (≤ 65 years) and geriatric patients (> 65 years).
Methods: Patients ≥ 16 years who sustained a severe TBI (Abbreviated Injury Scale of the head region > 3) were included in this prospective, multi-centre study. Outcome measures were Glasgow Outcome Scale Extended (GOSE; disability), SF-12 (HRQoL).